Defining secondary progressive multiple sclerosis
- PMID: 27401521
- DOI: 10.1093/brain/aww173
Defining secondary progressive multiple sclerosis
Abstract
A number of studies have been conducted with the onset of secondary progressive multiple sclerosis as an inclusion criterion or an outcome of interest. However, a standardized objective definition of secondary progressive multiple sclerosis has been lacking. The aim of this work was to evaluate the accuracy and feasibility of an objective definition for secondary progressive multiple sclerosis, to enable comparability of future research studies. Using MSBase, a large, prospectively acquired, global cohort study, we analysed the accuracy of 576 data-derived onset definitions for secondary progressive multiple sclerosis and first compared these to a consensus opinion of three neurologists. All definitions were then evaluated against 5-year disease outcomes post-assignment of secondary progressive multiple sclerosis: sustained disability, subsequent sustained progression, positive disability trajectory, and accumulation of severe disability. The five best performing definitions were further investigated for their timeliness and overall disability burden. A total of 17 356 patients were analysed. The best definition included a 3-strata progression magnitude in the absence of a relapse, confirmed after 3 months within the leading Functional System and required an Expanded Disability Status Scale step ≥4 and pyramidal score ≥2. It reached an accuracy of 87% compared to the consensus diagnosis. Seventy-eight per cent of the identified patients showed a positive disability trajectory and 70% reached significant disability after 5 years. The time until half of all patients were diagnosed was 32.6 years (95% confidence interval 32-33.6) after disease onset compared with the physicians' diagnosis at 36 (35-39) years. The identified patients experienced a greater disease burden [median annualized area under the disability-time curve 4.7 (quartiles 3.6, 6.0)] versus non-progressive patients [1.8 (1.2, 1.9)]. This objective definition of secondary progressive multiple sclerosis based on the Expanded Disability Status Scale and information about preceding relapses provides a tool for a reproducible, accurate and timely diagnosis that requires a very short confirmation period. If applied broadly, the definition has the potential to strengthen the design and improve comparability of clinical trials and observational studies in secondary progressive multiple sclerosis.
Keywords: MSBase; definition; disability; secondary progressive multiple sclerosis; study design.
© The Author (2016). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For Permissions, please email: journals.permissions@oup.com.
Similar articles
-
Defining reliable disability outcomes in multiple sclerosis.Brain. 2015 Nov;138(Pt 11):3287-98. doi: 10.1093/brain/awv258. Epub 2015 Sep 10. Brain. 2015. PMID: 26359291
-
Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple Sclerosis.JAMA Neurol. 2018 Nov 1;75(11):1407-1415. doi: 10.1001/jamaneurol.2018.2109. JAMA Neurol. 2018. PMID: 30083762 Free PMC article.
-
Association of Sustained Immunotherapy With Disability Outcomes in Patients With Active Secondary Progressive Multiple Sclerosis.JAMA Neurol. 2020 Nov 1;77(11):1398-1407. doi: 10.1001/jamaneurol.2020.2453. JAMA Neurol. 2020. PMID: 32716480 Free PMC article.
-
Pharmacological Approaches to the Management of Secondary Progressive Multiple Sclerosis.Drugs. 2017 May;77(8):885-910. doi: 10.1007/s40265-017-0726-0. Drugs. 2017. PMID: 28429241 Review.
-
Understanding the impact of relapses in the overall course of MS; refinement of the 2 stage natural history model.J Neuroimmunol. 2017 Apr 15;305:162-166. doi: 10.1016/j.jneuroim.2017.02.011. Epub 2017 Feb 16. J Neuroimmunol. 2017. PMID: 28284338 Review.
Cited by
-
Different Doses of Fingolimod in Relapsing-Remitting Multiple Sclerosis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Front Pharmacol. 2021 May 17;12:621856. doi: 10.3389/fphar.2021.621856. eCollection 2021. Front Pharmacol. 2021. PMID: 34079453 Free PMC article.
-
Can Selected Parameters of Brain Injury Reflect Neuronal Damage in Smoldering Multiple Sclerosis?Diagnostics (Basel). 2024 Sep 9;14(17):1993. doi: 10.3390/diagnostics14171993. Diagnostics (Basel). 2024. PMID: 39272777 Free PMC article.
-
Machine learning in secondary progressive multiple sclerosis: an improved predictive model for short-term disability progression.Mult Scler J Exp Transl Clin. 2019 Nov 6;5(4):2055217319885983. doi: 10.1177/2055217319885983. eCollection 2019 Oct-Dec. Mult Scler J Exp Transl Clin. 2019. PMID: 31723436 Free PMC article.
-
Clinical Evaluation of Siponimod for the Treatment of Secondary Progressive Multiple Sclerosis: Pathophysiology, Efficacy, Safety, Patient Acceptability and Adherence.Patient Prefer Adherence. 2022 May 24;16:1307-1319. doi: 10.2147/PPA.S221882. eCollection 2022. Patient Prefer Adherence. 2022. PMID: 35637684 Free PMC article. Review.
-
Considering patient clinical history impacts performance of machine learning models in predicting course of multiple sclerosis.PLoS One. 2020 Mar 20;15(3):e0230219. doi: 10.1371/journal.pone.0230219. eCollection 2020. PLoS One. 2020. PMID: 32196512 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources